A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer's Disease

Author： Kirbach Stephanie  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.28, Iss.5, 2008-01, pp. : 291-303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Memantine in Alzheimer’s Disease: An Analysis Based on a Probabilistic Markov Model from a UK Perspective

By Roy W. Jones  

Drugs & Aging, Vol. 21, Iss. 9, 2004-01 ,pp. : 607-620

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s Disease: A Markov Model in Finland

By François C.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 373-384

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting: An Economic Markov Model Evaluation

By Haycox Alan  

Drugs & Aging, Vol. 26, Iss. 9, 2009-09 ,pp. : 791-801

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting:: An Economic Markov Model Evaluation

By Kovacs Norbert   Janszky Jozsef   Nagy Ferenc  

Drugs & Aging, Vol. 28, Iss. 2, 2011-02 ,pp. : 161-162

Adis International

Access to resources Recommend Favorite

Olanzapine worth it for agitation, psychosis in AD

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 553, 2008-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite